GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.

ABSTRACT:

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as potential neuroprotective agents for Parkinson's disease (PD). However, evidence regarding their efficacy remains inconclusive.

Objective

To assess the therapeutic effects and safety profile of GLP-1 RAs in patients with mild-to-moderate PD. We aim to conduct an updated systematic review to evaluate the effects of GLP-1 RAs in patients with mild-to-moderate PD.

Design

Systematic review and meta-analysis of randomized controlled trials (RCTs) with trial sequential analysis (TSA) and Grading of Recommendations, Assessment, Development, and Evaluations certainty assessment.

Data sources

PubMed, Embase, and the Cochrane Library were searched through April 14, 2025.

Methods

We co

SUBMITTER: Tsai WW 

PROVIDER: S-EPMC12426393 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature